Nuwellis, Inc. Plans to Share Third Quarter Financial Results
Nuwellis, Inc. (NASDAQ: NUWE), a pioneering medical technology firm, is gearing up to reveal its financial results for the third quarter of 2024. This announcement is scheduled for a Monday, where the company aims to shed light on its performance and progress in transforming the lives of individuals grappling with fluid overload.
Conference Call and Business Update
The spotlight will be on Nuwellis as it conducts a conference call and webcast at 9:00 AM ET. This event will serve as an opportunity for investors and analysts to gain insights into the company’s financial health and future direction. The management team will not only discuss the quarterly financials but also provide a general business update, offering a comprehensive view of the company’s strategies and developments.
How to Participate
For those looking to join the live webcast, details can be found on the Investors page of Nuwellis’s website. Interested parties may also opt for the conference call by calling the designated numbers provided during the event. The audio archive of the webcast will be made available shortly after the call, ensuring that stakeholders can catch up on what they missed.
Company Overview
Nuwellis, Inc. is committed to advancing medical technology with a focus on alleviating fluid overload conditions. With its headquarters in Minneapolis and a subsidiary in Ireland, the company is known for its innovative Aquadex SmartFlow® system designed for ultrafiltration therapy. This system is pivotal for patients suffering from hypervolemia, offering a clinically proven therapy that successfully removes excess fluid from affected individuals.
The Importance of Aquadex SmartFlow® System
This groundbreaking system is intended for patients who do not respond effectively to traditional medical management methods, including diuretics. The Aquadex SmartFlow system is suitable for temporary or extended applications, targeting both adult and pediatric patients over 20 kg. Due to its intricacies, treatments are exclusively administered by healthcare providers who have received specialized training in extracorporeal therapies, emphasizing safety and efficacy.
Investor Relations Contact
Interested investors can reach out to Vivian Cervantes at Gilmartin Group LLC for any inquiries related to the company’s performance or financial matters. Email communication is open for those seeking more detailed insights into Nuwellis and its market position.
Frequently Asked Questions
What is the date for Nuwellis's Q3 earnings announcement?
Nuwellis plans to announce its Q3 financial results on November 11, 2024.
What is the Aquadex SmartFlow® system?
The Aquadex SmartFlow system is a medical device designed for ultrafiltration therapy to help patients suffering from fluid overload.
How can investors participate in the earnings call?
Investors can join the earnings call by dialing the provided numbers or accessing the live webcast via the Nuwellis Investors page.
What type of patients benefit from the Aquadex SmartFlow system?
The system is intended for adult and pediatric patients over 20 kg who experience fluid overload not responsive to traditional treatments.
How can I contact Nuwellis’s investor relations?
Investors can reach out to Vivian Cervantes at Gilmartin Group LLC, or via the provided investor email for inquiries.
